REGULATORY

Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication

February 7, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Eli Lilly’s RET kinase inhibitor Retevmo (selpercatinib) sailed through reviews by a key health ministry advisory panel on February 4 for two additional indications for use in certain patients with thyroid cancer and medullary thyroid cancer. The Pharmaceutical Affairs and…

To read the full story

MHLW Approves Label Expansions for Retevmo, Keytruda, Lenvima and More
February 28, 2022

REGULATORY

MHLW Issues Q&A on Conditional Approval System
May 1, 2026
Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…